Comparison · NCT02291237-sae
Eleclazine 30/3/6 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Eleclazine 30/3/6 mg vs Placebo: serious adverse events. Trial comparisons, record NCT02291237-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02291237-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.163 | 0.0995 | 0.255 | wilson | |
| Risk in group 2 | 0.186 | 0.118 | 0.281 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0233 | -0.137 | 0.0913 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.875 | 0.456 | 1.68 | log | |
| Odds ratio, group 1 over group 2 | 0.851 | 0.386 | 1.87 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Eleclazine 30/3/6 mg than on Placebo | 43 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Eleclazine 30/3/6 mg | Single loading dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1, followed by 3 mg (1 x 3 mg tablet) daily maintenance dose until Week 12, then 6 mg (2 x 3 mg tablets) daily maintenance dose from Week 12 to at least Week 24 | 14 | 86 | EG000 |
| Group 2 | Placebo | Placebo to match eleclazine administered orally for at least 24 weeks | 16 | 86 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline up to the last dose date plus 30 days (maximum exposure: 668 days)
Source ClinicalTrials.gov
Trial
- Title
- Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
- NCT number
- NCT02291237
- Phases
- PHASE2, PHASE3
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Eleclazine, Placebo
- Lead sponsor
- Gilead Sciences
- Results first posted
- 2018-03-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02291237?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02291237-sae